Saturday, May 31, 2003

Conference Attendees at ASCO 2003

A Phase II Study of Docetaxel and Carboplatin as Neoadjuvant Therapy for Patients with Early T and Advanced N Stage Nasopharyngeal Carcinoma(NPC) Presenter: FM JohnsonPresenter's Affiliation: The University of Texas M.D. Anderson Cancer CenterType of Session: PosterBackground Historically, early stage NPC has been treated successfully with radiation therapy. Radiation therapy alone provides...
Age-Specific Sub-Analysis of ECOG 1594: Fit Elderly Patients (70-80 yrs) with Non-Small Cell Lung Cancer Do As Well As Younger Patients (<70 yrs) Presenter: CJ LangerPresenter's Affiliation: Fox Chase Cancer CenterType of Session: PosterBackground Exclusion of elderly patients from studies of advanced non-small cell lung cancer (NSCLC) has been common due to fear of increased toxicity of...
Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02 Presenter: H.M. SandlerPresenter's Affiliation: RTOGType of Session: ScientificBackground Prostate cancer is a disease with a long natural history, so the use of survival as an endpoint requires a very long follow-up to reach conclusions Therefore,...
Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT 0101) Presenter: N. E. DavidsonPresenter's Affiliation: Eastern Cooperative Oncology GroupType of Session: ScientificBackground The benefits of combined chemotherapy and endocrine therapy in premenopausal pts with node-positive, hormone receptor-positive...
Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update Presenter: M. A. EisenbergerPresenter's Affiliation: Johns Hopkins University (JHU)Type of Session: ScientificBackground Post-prostatectomy patients demonstrating biochemical evidence of prostate cancer recurrence have been previously studied with...
Older women with node positive (N+) breast cancer (BC) get similar benefits from adjuvant chemotherapy (adj) as younger patients (pts): The Cancer and Leukemia Group B (CALGB) experience Presenter: H. B. MussPresenter's Affiliation: Univ. of Vermont, CALGBType of Session: ScientificBackground This study is an analysis of the benefits and toxicities by age of adjuvant chemotherapy in N+ breast cancer patients. Little data exists...
P53, EGFR, and PTEN as markers of diagnosis and prognosis in patients with anaplastic glioma enrolled in NCCTG clinical trials Presenter: J.C. BucknerPresenter's Affiliation: NCCTGType of Session: ScientificBackground The NCCTG has previously reported survival differences in patients with high grade gliomas. Median survival times were 52 mo, 19 mo, 16 mo, and 11 mo for...
Paclitaxel (T) following doxorubicin/cyclophosphamide(AC) as adjuvant chemotherapy for node positive breast cancer: Results from NSABP B-28 Presenter: E. P. MamounasPresenter's Affiliation: NSABPType of Session: ScientificBackground This prospective randomized trial intended to determine whether the addition of T to AC chemotherpy provided a benefit in node positive patients with...
Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. Presenter: M.V. PilepichPresenter's Affiliation: RTOGType of Session: ScientificBackground RTOG 85-31 was one of the first studies investigating adjuvant androgen suppression in the treatment of prostate cancer. Since the publication of this study,...
Pulmonary radiological-, physiological-, and clinical side-effects after adjuvant radiotherapy in breast cancer Presenter: P.A. LindPresenter's Affiliation: Karolinska Institute, SwedenType of Session: PosterBackground Adjuvant radiation therapy used in the treatment of breast cancer has been shown to decrease cancer deaths However, toxicity from radiation...
Randomized Phase III Study of I.V. Vinorelbine plus hormonotherapy versus hormonotherapy alone in hormone refractory prostate cancer (HRPC) Presenter: R.P AbrettPresenter's Affiliation: Groote Schuur Hospital, Cape Town, South AfricaType of Session: ScientificBackground Vinorelbine has been shown to be active in hormone refractory prostate cancer. Controversy exists regarding the proper...
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy Presenter: M. G. Le ArriagadaPresenter's Affiliation: Institut Gustave-RoussyType of Session: ScientificBackground Premenopausal women with early breast cancer receive a significant reduction in overall mortality from adjuvant ovarian suppression...
The role of hormonal treatment for biochemical recurrence in patients following radical prostatectomy Presenter: Z. A. DotanPresenter's Affiliation: Memorial Sloan Kettering Cancer CenterType of Session: ScientificBackground Biochemical failure following radical prostatectomy (RP) is common, occurring in 20-40% of patients. 1/4 to 1/3 of these...
Treatment of Elderly Non-Small Lung Cancer (NSCLC) Patients with 3 Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial Presenter: S. RamalingamPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: PosterBackground Benefit from combination chemotherapy extends to all age patients with advanced NSCLC Elderly patients with good performance...
Two year survival for Concurrent Carboplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Unresectable Head and Neck Cancer. Presenter: D. CarterPresenter's Affiliation: US Oncology, Houston TXType of Session: PosterBackground Several randomized trials and meta-analyses have shown superior local control, disease-free and overall survival for simultaneous chemoradiotherapy...
Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. Presenter: A. V. D'AmicoPresenter's Affiliation: Dana-Farber Cancer InstituteType of Session: ScientificBackground Various algorithms using pre-treatment risk groups to predict for PSA failure in prostate cacner patients currently exist, namely...